Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Scott Daniels

Showing results (61-70 of 122) with videos related to

Pageof 13
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 19, 2016
N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodentsAndrew S Felts, Alice L Rodriguez, Ryan D Morrison, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2013
Discovery of ML326: The first sub-micromolar, selective M5 PAMPatrick R Gentry, Thomas M Bridges, Atin Lamsal, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 23, 2014
Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profilesJerri M Rook, Mohammed N Tantawy, Mohammad S Ansari, et al.
The Journal of Infectious Diseases|April 18, 2015
VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral LeishmaniasisGalina I Lepesheva, Tatiana Y Hargrove, Girish Rachakonda, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2013
Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit bindingMark Turlington, Aspen Chun, Sakshi Tomar, et al.
Journal of Medicinal Chemistry|August 23, 2014
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)Patrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012Bruce J Melancon, Thomas J Utley, Christian Sevel, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probePaul R Reid, Thomas M Bridges, Douglas J Sheffler, et al.
Human Molecular Genetics|March 4, 2016
mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndromeRocco G Gogliotti, Rebecca K Senter, Jerri M Rook, et al.
Bioorganic & Medicinal Chemistry Letters|September 2, 2014
Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354Wandong Wen, Summer E Young, Matthew T Duvernay, et al.
Pageof 13

Showing results (61-70 of 122) with videos related to

Sort By:
Pageof 13
Bioorganic & Medicinal Chemistry Letters|March 19, 2016
N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodentsAndrew S Felts, Alice L Rodriguez, Ryan D Morrison, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2013
Discovery of ML326: The first sub-micromolar, selective M5 PAMPatrick R Gentry, Thomas M Bridges, Atin Lamsal, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 23, 2014
Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profilesJerri M Rook, Mohammed N Tantawy, Mohammad S Ansari, et al.
The Journal of Infectious Diseases|April 18, 2015
VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral LeishmaniasisGalina I Lepesheva, Tatiana Y Hargrove, Girish Rachakonda, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2013
Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit bindingMark Turlington, Aspen Chun, Sakshi Tomar, et al.
Journal of Medicinal Chemistry|August 23, 2014
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)Patrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012Bruce J Melancon, Thomas J Utley, Christian Sevel, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probePaul R Reid, Thomas M Bridges, Douglas J Sheffler, et al.
Human Molecular Genetics|March 4, 2016
mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndromeRocco G Gogliotti, Rebecca K Senter, Jerri M Rook, et al.
Bioorganic & Medicinal Chemistry Letters|September 2, 2014
Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354Wandong Wen, Summer E Young, Matthew T Duvernay, et al.
Pageof 13